Clinical trials: Diabetes Mellitus Type II
Diabetes Mellitus Type 2
Safety and Efficacy Study of EGT0001442 in Subjects With Type 2 Diabetes Mellitus
The purpose of this study was to assess the effect of EGT0001442 on fasting plasma glucose after 28 days of treatment in subjects with type 2 diabetes.
- Trial name
- NCT01029704
- Testing
- EGT0001442
- Where
- 12 sites in United States, Canada
- Volunteers
- 151 people
- Sponsor
- Theracos
Diabetes, Diabetes Mellitus, Type 1
An Observational Study to Assess Safety and Effectiveness of Intravenous NovoRapid® in Hospitalised Subjects
This study is conducted in Asia. The aim of this observational study is to evaluate the side effects profile and benefits of using intravenous insulin aspart infusion in hospitalised subjects under normal clinical practice…
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT00700648
- Testing
- insulin aspart
- Where
- India
- Volunteers
- 3,024 people
- Sponsor
- Novo Nordisk A/S
Weight Loss, Metabolic Syndrome
Signos DM2 Empowerment Study (SIGNOS-CGM-EMPOWER-201-2022)
The use of continuous glucose monitoring (CGM) in earlier data has inspired behavioral changes leading to improved adherence to an exercise plan in individuals and eating habits in people with diabetes.
- Conditions
- Weight Loss, Metabolic Syndrome, Diabetes Mellitus, Type 2, Central Obesity
- Trial name
- NCT05874635
- Testing
- Continuous Glucose Monitor Device
- Where
- United States
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- Signos Inc
Type 1 Diabetes, Type 2 Diabetes
A Study of LY8888AX in Participants Using a Connected Insulin Management Platform
The main purpose of this study is to assess participant adherence and glucose control while using a connected insulin management platform. Approximately 50 participants will be enrolled in each country.
- Conditions
- Type 1 Diabetes, Type 2 Diabetes, Type 2 Diabetes Treated With Insulin
- Trial name
- NCT05893797
- Testing
- Insulin Lispro, Tempo Smart Button, Dexcom G6 CGM
- Where
- 9 sites in France
- Volunteers
- 36 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes
A Study to Evaluate the Pharmacokinetics and Safety Between Single Oral Administration of BR3006 and Co-administration of BR3006A, BR3006B and BR3006C in Healthy Adult Volunteers Under Fasting Conditions
The purpose of this clinical study is to evaluate the pharmacokinetics and safety between single oral administration of BR3006 and co-administration of BR3006A, BR3006B and BR3006C in healthy adult volunteers under fasting…
- Trial name
- NCT06890286
- Testing
- BR3006, BR3006A, BR3006B
- Where
- South Korea
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Type 2 Diabetes Mellitus
A Phase IV Study in Drug-Naive Patients With T2DM in China
This is a 24-week, multicenter, randomized, open-label, parallel-group, active controlled Phase IV study to assess the efficacy and safety of Dapagliflozin as monotherapy compared with Acarbose in patients with T2DM who were…
- Trial name
- NCT03344341
- Testing
- Dapagliflozin, Acarbose
- Where
- 20 sites in China
- Volunteers
- 304 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
Efficacy and Safety of Linagliptin in Elderly Patients With Type 2 Diabetes
The objective of the current study is to investigate the efficacy, safety and tolerability of linagliptin (5 mg / once daily) compared to placebo given for 24 weeks as add-on therapy to stable treatment in elderly patients with…
- Trial name
- NCT01084005
- Testing
- linagliptin
- Where
- 34 sites in Australia, Canada and 3 more
- Volunteers
- 241 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2, Chronic Renal Insufficiency
An Investigational Drug in Patients With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency (0431-028)(COMPLETED)
The purpose of this study is to determine the safety and tolerability of an investigational drug in patients with Type 2 Diabetes Mellitus (a specific type of diabetes) and Chronic Renal Insufficiency (inadequate kidney function).
- Trial name
- NCT00095056
- Testing
- sitagliptin, glipizide
- Volunteers
- 91 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus
A Pilot Open Label Clinical Trial to Evaluate the Combined Impact of Two Mobile Health Products on Health Outcomes in Overweight Adults With Type 2 Diabetes
The purpose of this study is to explore the effect of 8-weeks use of the Medidata Patient Cloud (a mobile application for capturing data directly from subjects, enabling entry of diary and quality of life data into…
- Trial name
- NCT02227303
- Testing
- lifestyle modification instructional and motivational sessions
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Medidata Solutions
Diabetes Mellitus, Type 2, Obesity
A Research Study Looking Into Blood Levels of the Medicine NNC0487-0111 in the Body and How Well it is Tolerated in Participants With Reduced Kidney Function and Normal Kidney Function
Novo Nordisk is developing the study medicine NNC0487-0111 to treat people living with type 2 diabetes and/or people living with overweight or obesity.
- Conditions
- Diabetes Mellitus, Type 2, Obesity, Overweight
- Trial name
- NCT06559527
- Testing
- NNC0487-0111
- Where
- Germany
- Volunteers
- 42 people
- Sponsor
- Novo Nordisk A/S
Chronic Kidney Diseases
CLBS201 in Patients with Chronic Kidney Disease (CKD) and Type 2 Diabetes Mellitus (T2DM)
CLBS201 will evaluate the safety, tolerability, and therapeutic effect in subjects with CKD and T2DM.
- Trial name
- NCT04990427
- Testing
- CLBS201
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Lisata Therapeutics, Inc.
Diabetes Mellitus, Type 2, Non-Insulin-Dependent Diabetes Mellitus
GSK189075, GW869682 Or Placebo In Type 2 Diabetic Patients
This is a study to compare the safety, blood concentrations, and effects of GSK189075, GW869682, and placebo when dosed for 2-weeks by mouth to patients with type 2 diabetes.
- Trial name
- NCT00291356
- Testing
- GSK189075 oral tablets, GW869682 oral tablets
- Where
- 3 sites in United States, Germany
- Volunteers
- 45 people
- Sponsor
- GlaxoSmithKline
Type 2 Diabetes
A Multiple-Dose Study of MK-1006 (MK-1006-004)(TERMINATED)
This study will asses the safety, tolerability, multiple-dose pharmacokinetics and pharmacodynamics of MK1006 in participants with type 2 diabetes.
- Trial name
- NCT00758680
- Testing
- MK-1006
- Volunteers
- 112 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 2
Developing Affective HeaLth to Improve Adherence to Health Behaviors in Diabetes (DAHLIA II)
Participants will be randomly assigned to either a positive affect skills intervention or a psychoeducation control group and assessed with questionnaires before, during, and after the 8-week program, as well as at 3 months, 6…
- Trial name
- NCT04068805
- Testing
- Happify
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Happify Inc.
Overweight, Obesity
Study of Gelesis100 on Body Weight in Overweight and Obese Subjects With and Without Type 2 Diabetes
This study will asses the decrease in body weight after repeated administration of Gelesis100 in overweight and obese subjects with and without Type 2 Diabetes.
- Trial name
- NCT02307279
- Testing
- Gelesis100
- Where
- 36 sites in United States, Canada and 4 more
- Volunteers
- 436 people
- Sponsor
- Gelesis, Inc.
Type 2 Diabetes Mellitus (T2DM)
Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) Assessment of LIK066 in Healthy Subjects and in Patients With Type 2 Diabetes Mellitus (T2DM)
This study will assess safety, tolerability, and effect of LIK066 on blood glucose in healthy subjects and in patients with T2DM.
- Trial name
- NCT01407003
- Testing
- LIK066
- Where
- United States
- Volunteers
- 138 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Diabetes Mellitus, Type 2
A Clinical Study to Evaluate the Use of Episodic, Intensive Blood Glucose Monitoring in Persons With Non-insulin Treated Type 2 Diabetes
This randomized, parallel group study will determine whether the use of episodic, intensive glucose monitoring via the Accu-Chek 360 view blood glucose analysis system has a positive effect on overall glycemic control.
- Trial name
- NCT00674986
- Testing
- Accu-Chek 360° View Blood Glucose Analysis Tool, Accu-Chek Aviva Glucose Meter
- Where
- 29 sites in United States
- Volunteers
- 522 people
- Sponsor
- Hoffmann-La Roche
Diabetes Mellitus, Type 2
Efficacy and Safety of Insulin Rinsulin® NPH Compared to Humulin® NPH in Type 2 Diabetes Mellitus Patients
The study is designed to approve non-inferior efficacy and safety of Rinsulin® NPH compared to Humulin® NPH.
- Trial name
- NCT04012775
- Testing
- Insulin Humulin® NPH, Insulin Rinsulin® NPH
- Where
- 14 sites in Russia
- Volunteers
- 201 people
- Sponsor
- Geropharm
Diabetes Mellitus, Type 2
Evaluation of Pharmacokinetics and Safety of AJU-A51 in Healthy Adults
To evaluate the safety and pharmacokinetic characteristics of AJU-A51 in healthy adults
- Trial name
- NCT04972539
- Testing
- AJU-A51 Tab., A51R1 Tab. and A51R2 Tab.
- Where
- South Korea
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- AJU Pharm Co., Ltd.
Prediabetes, Type 2 Diabetes
Effect of Totum-63, Active Ingredient of Valedia, on Glucose and Lipid Homeostasis on Subjects With Prediabetes
Given the data on the active ingredients of Totum-63, this research aims to evaluate the effect of its chronic consumption (24 weeks) on glucose and lipid homeostasis and especially on fasting plasma glucose in volunteers with…
- Conditions
- Prediabetes, Type 2 Diabetes, Hypertriglyceridemia, Obesity
- Trial name
- TOTUM-63 TWO (NCT02868177)
- Testing
- Totum-63
- Where
- 6 sites in France, Ireland and 2 more
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Valbiotis
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.